# Phase 2 Dendritic Cell Sarcoma: 23 recruiting (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 2 for Dendritic Cell Sarcoma, Interdigitating that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Dendritic Cell Sarcoma, Interdigitating trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/dendritic-cell-sarcoma-interdigitating

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 10, 2026 | NCT07812493 | Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic Lymphoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812493) |
| August 6, 2026 | NCT07749365 | Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL | The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma) | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749365) |
| August 5, 2026 | NCT07748364 | Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748364) |
| August 4, 2026 | NCT07744750 | Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma | Changzhou No.2 People's Hospital | Phase 2 | Not yet recruiting | DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL, MZL | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744750) |
| August 4, 2026 | NCT07744737 | Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL | Changzhou No.2 People's Hospital | Phase 2 | Not yet recruiting | DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, Pirtobrutinib | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744737) |
| August 4, 2026 | NCT07744724 | Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL | Changzhou No.2 People's Hospital | Phase 2 | Not yet recruiting | DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744724) |
| July 2, 2026 | NCT07680933 | Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for... | The Affiliated Hospital of Xuzhou Medical University | Phase 2 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680933) |
| July 1, 2026 | NCT07677813 | Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | DLBCL - Diffuse Large B Cell Lymphoma | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677813) |
| April 27, 2026 | NCT07552324 | Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP | Ruijin Hospital | Phase 2 | Not yet recruiting | DHL, THL, DLBCL - Diffuse Large B Cell Lymphoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552324) |
| January 8, 2026 | NCT07326371 | Glofitamab Combined With CAR-T Therapy in R/R DLBCL | Ruijin Hospital | Phase 2 | Not yet recruiting | DLBCL - Diffuse Large B Cell Lymphoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326371) |
| December 17, 2025 | NCT07288879 | DALY II Japan/MB-CART2019.1 for DLBCL | Miltenyi Biomedicine GmbH | Phase 2 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288879) |
| December 1, 2025 | NCT07255963 | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07255963) |
| November 17, 2025 | NCT07231250 | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy, Bispecific Antibody | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07231250) |
| June 24, 2025 | NCT07034508 | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | DLBCL - Diffuse Large B Cell Lymphoma | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07034508) |
| April 9, 2025 | NCT06919939 | Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma | University of Miami | Phase 2 | Recruiting | Large B-cell Lymphoma, Relapse, DLBCL, DLBCL - Diffuse Large B Cell Lymphoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06919939) |
| March 24, 2025 | NCT06891157 | Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL) | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06891157) |
| February 26, 2025 | NCT06846463 | Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ | Virginia Commonwealth University | Phase 2 | Recruiting | Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06846463) |
| January 16, 2025 | NCT06778902 | AZA Combined with R-GemOx for Elderly DLBCL Patients | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 | Not yet recruiting | DLBCL - Diffuse Large B Cell Lymphoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06778902) |
| December 17, 2024 | NCT06736613 | A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Stage III High Grade B-Cell Lymphoma, Stage IV High Grade... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06736613) |
| August 2, 2024 | NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | Zhejiang Provincial People's Hospital | Phase 2 | Recruiting | NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer, TNBC - Triple-Negative Breast Cancer, DLBCL - Diffuse Large B Cell... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06534762) |
| March 1, 2024 | NCT06287398 | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | Australasian Leukaemia and Lymphoma Group | Phase 2 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6... | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06287398) |
| December 6, 2023 | NCT06158399 | AZA Combined With RCHOP in P53-mutated DLBCL. | The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma, TP53 | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06158399) |
| November 30, 2023 | NCT06151080 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06151080) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Changzhou No.2 People's Hospital | 3 |
| The First Affiliated Hospital of Xiamen University | 3 |
| Ruijin Hospital | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Australasian Leukaemia and Lymphoma Group | 1 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 1 |
| Zhejiang Provincial People's Hospital | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Virginia Commonwealth University | 1 |
| The Affiliated Hospital of Xuzhou Medical University | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 1 |
| University of Miami | 1 |
| The First Affiliated Hospital of Soochow University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 15 |
| United States | 4 |
| Australia | 1 |
| Japan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical transportation companies in the United States](https://specstream.ai/data/businesses/medical-transportation-companies/united-states)
- [Acoustical consultants in the United States](https://specstream.ai/data/businesses/acoustical-consultants/united-states)
- [Foundation repair contractors in the United States](https://specstream.ai/data/businesses/foundation-repair-contractors/united-states)
- [Roofing contractors in the United States](https://specstream.ai/data/businesses/roofing-contractors/united-states)
- [Chemical plants in the United States](https://specstream.ai/data/businesses/chemical-plants/united-states)
- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
